Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome

被引:32
|
作者
Luque-Ramirez, Manuel [1 ,2 ]
Mendieta-Azcona, Covadonga [3 ]
Alvarez-Blasco, Francisco [1 ,2 ]
Escobar-Morreale, Hector F. [1 ,2 ]
机构
[1] Hosp Univ Ramon y Cajal, Dept Endocrinol, E-28034 Madrid, Spain
[2] Univ Alcala, Madrid, Spain
[3] Hosp Univ La Paz, Dept Vasc Surg, Madrid, Spain
关键词
Androgens; insulin resistance; hypertension; metformin; oral contraceptives; atherosclerosis; YOUNG-WOMEN; INSULIN-RESISTANCE; ORAL-CONTRACEPTIVES; MAJOR DETERMINANT; RISK; PREVALENCE; DISEASE; OBESITY;
D O I
10.1016/j.fertnstert.2008.03.082
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the effects of metformin versus an antiandrogenic contraceptive pill on ambulatory blood pressure monitoring (ABPM) and carotid intima media thickness (CIMT) in women with polycystic ovary syndrome (PCOS). Design: Clinical randomized trial. Setting: Academic hospital. Patient(s): Thirty-four consecutive PCOS patients. Intervention(s): PCOS patients randomized to oral treatment with metformin (n = 19) or with Diane(35) Diario pill (n = 15) for 24 weeks. Main Outcome Measure(S): ABPM recordings and ultrasound measurements of CIMT as marker of subclinical atherosclerosis obtained at baseline and after treatment. Result(s): Metformin resulted in reductions in daytime and 24-hour average systolic and diastolic blood pressure whereas Diane(35) Diario induced a slight increase in these parameters. Compared with a nonhyperandrogenic control group, the increased CIMT values of PCOS patients decreased to the normal range after treatment with either metformin or Diane(35) Diario. Conclusion(s): Metformin treatment decreased daytime ABPM recordings whereas Diane(35) Diario exerted the opposite effect. The safer blood pressure profile of metformin should be considered in PCOS patients who present with a history of hypertension or who are at risk for this disorder. Treatment with either Diane(35) Diario or metformin improved CIMT mean values. (Fertil Steril (R) 2009;91:2527-36. (c) 2009 by American Society for Reproductive Medicine.)
引用
收藏
页码:2527 / 2536
页数:10
相关论文
共 50 条
  • [1] The Effects of Metformin, Ethinyl Estradiol/Cyproterone Acetate, and Metformin Ethinyl Estradiol/Cyproterone Acetate Combination Therapy on Carotid Artery Intima-media Thickness in Patients with Polycystic Ovary Syndrome
    Unal, Derya
    Demirci, Huseyin
    Yilmaz, Murat
    Kisa, Ucler
    Tulmac, Murat
    Guliter, Sefa
    ISTANBUL MEDICAL JOURNAL, 2020, 21 (01): : 47 - 52
  • [2] Comparison of ethinyl-estradiol plus cyproterone acetate Versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome
    Luque-Ramirez, Manuel
    Alvarez-Blasco, Francisco
    Botella-Carretero, José I.
    Martinez-Bermejo, Elena
    Lasuncion, Miguel A.
    Escobar-Morreale, Héctor F.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07): : 2453 - 2461
  • [3] Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome
    Karabulut, Aysun
    Demirlenk, Semra
    Sevket, Osman
    GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (04) : 245 - 248
  • [4] Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome:: A randomized study
    Morin-Papunen, L
    Vauhkonen, I
    Koivunen, R
    Ruokonen, A
    Martikainen, H
    Tapanainen, JS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01): : 148 - 156
  • [5] Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome:: A randomized study
    Morin-Papunen, LC
    Vauhkonen, I
    Koivunen, RM
    Ruokonen, A
    Martikainen, HK
    Tapanainen, JS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09): : 3161 - 3168
  • [6] Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome
    Mitkov, M
    Pehlivanov, B
    Terzieva, D
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2005, 118 (02) : 209 - 213
  • [7] Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome:: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin
    Luque-Ramirez, Manuel
    Alvarez-Blasco, Francisco
    Uriol Rivera, Miguel Giovanni
    Escobar-Morreale, Hector F.
    HUMAN REPRODUCTION, 2008, 23 (07) : 1594 - 1601
  • [8] Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome
    Wu, Jie
    Zhu, Yiqing
    Jiang, Yunfei
    Cao, Yaoping
    GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (07) : 392 - 398
  • [9] Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial
    Leelaphiwat, Supatra
    Jongwutiwes, Theerayut
    Lertvikool, Srithean
    Tabcharoen, Chotika
    Sukprasert, Matchuporn
    Rattanasiri, Sasivimol
    Weerakiet, Sawaek
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2015, 41 (03) : 402 - 410
  • [10] Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome
    Rautio, K
    Tapanainen, JS
    Ruokonen, A
    Morin-Papunen, LC
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (02) : 269 - 275